Effect of novel Matrix Rhythm Therapy (MaRhyThe®) on neuropathic pain and maximum plantar pressure distribution among type 2 diabetes mellitus patients with peripheral neuropathy

• Published in: Journal of diabetes and metabolic disorders Vol. 22; no. 1; pp. 827 - 833
• Main Authors: Maiya, G Arun, Jadhav, Radhika Aditya, Harihar, Anupama, Gundmi, Shubha, Shetty, Amratha G., Yadav K, Hrishikesh, Hammond, Ozlem, Randoll, Ulrich G, Deshpande, Anil, Mayya, Shreemathi, Naik, Varun C
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 19.04.2023; BioMed Central Ltd
• Subjects: Analysis; Care and treatment; Diabetes; Endocrinology; Health aspects; Medicine; Medicine & Public Health; Metabolic Diseases; Pain; Research Article; Type 2 diabetes; Extracellular matrix (ECM); Matrix Rhythm Therapy; Plantar pressure; Type 2 diabetes mellitus; Diabetic peripheral neuropathy
• ISSN: 2251-6581; 2251-6581
• DOI: 10.1007/s40200-023-01210-8

Background There is a need for a non-pharmacological approach to reduce pain and plantar pressure in diabetic peripheral neuropathy (DPN). Matrix Rhythm Therapy (MaRhyThe®) is a therapeutic modality that works on the principle of physiologic rhythmic oscillations of the body cells. This study aimed to evaluate the effect of MaRhyThe® on neuropathic pain and maximum plantar pressure distribution among type 2 diabetes mellitus patients with peripheral neuropathy. Materials and methods A total of 33 participants with DPN were recruited for the study based on inclusion criteria. Maximum plantar pressure was recorded using Win-Track 11K005, and the pain score was obtained using a visual analogue scale. Ten sessions of MaRhyThe® were given to all the participants. Outcome measures were evaluated at the baseline and after 10th session. Paired t-test was performed to analyze the changes in outcome measures. Results Participants of DPN were recruited with the average age of 64 ± 9 years, and an average duration of diabetes was 14 ± 9 years were included. Results of the present study found significant improvement in neuropathic pain and plantar pressure in post intervention assessment. (p < 0.05) Conclusion In the present study, we found that MaRhyThe® is effective in reducing neuropathic pain and maximum plantar pressure in type 2 diabetes mellitus with peripheral neuropathy.